Imatinib mesylate inhibits CD4(+)CD25(+) regulatory T cell activity and enhances active immunotherapy against BCR-ABL(negative) tumors

Imatinib mesylate (Gleevec, STI571), a selective inhibitor of a restricted number of tyrosine kinases, has been effectively used for the treatment of Philadelphia chromosome positive leukemias and gastrointestinal stromal tumors. Imatinib may also directly influence immune cells. Suppressive as well...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Larmonier, Nicolas, Janikashvili, Nona, LaCasse, Collin J., Larmonier, Claire B., Cantrell, Jessica, Situ, Elaine, Lundeen, Tamara, Bonnotte, Bernard, Katsanis, Emmanuel
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2579962/
https://ncbi.nlm.nih.gov/pubmed/18981115
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados